



# Using machine learning to model dose–response relationships

Ariel Linden DrPH,<sup>1,2</sup> Paul R Yarnold PhD<sup>3,4</sup> and Brahmajee K Nallamothu MD MPH<sup>5</sup>

<sup>1</sup>President, Linden Consulting Group, LLC, Ann Arbor, MI, USA

<sup>2</sup>Research Scientist, Division of General Medicine, Medical School–University of Michigan, Ann Arbor, MI, USA

<sup>3</sup>Principal Scientist, Optimal Data Analysis, LLC, Chicago, IL, USA

<sup>4</sup>Statistician, Southern Network on Adverse Reactions (SONAR), College of Pharmacy, University of South Carolina, Columbia, SC, USA

<sup>5</sup>Professor, Division of Cardiovascular Diseases, Department of Internal Medicine, Medical School–University of Michigan, Ann Arbor, MI, USA

## Keywords

adherence, data mining, dose–response, efficacy, machine learning

## Correspondence

Ariel Linden  
Linden Consulting Group, LLC,  
1301 North Bay Drive  
Ann Arbor, MI 48103, USA  
E-mail: alinden@lindenconsulting.org

Accepted for publication: 3 May 2016

doi:10.1111/jep.12573

## Abstract

**Rationale, aims and objectives** Establishing the relationship between various doses of an exposure and a response variable is integral to many studies in health care. Linear parametric models, widely used for estimating dose–response relationships, have several limitations. This paper employs the optimal discriminant analysis (ODA) machine-learning algorithm to determine the degree to which exposure dose can be distinguished based on the distribution of the response variable. By framing the dose–response relationship as a classification problem, machine learning can provide the same functionality as conventional models, but can additionally make individual-level predictions, which may be helpful in practical applications like establishing responsiveness to prescribed drug regimens.

**Method** Using data from a study measuring the responses of blood flow in the forearm to the intra-arterial administration of isoproterenol (separately for 9 black and 13 white men, and pooled), we compare the results estimated from a generalized estimating equations (GEE) model with those estimated using ODA.

**Results** Generalized estimating equations and ODA both identified many statistically significant dose–response relationships, separately by race and for pooled data. *Post hoc* comparisons between doses indicated ODA (based on exact *P* values) was consistently more conservative than GEE (based on estimated *P* values). Compared with ODA, GEE produced twice as many instances of paradoxical confounding (findings from analysis of pooled data that are inconsistent with findings from analyses stratified by race).

**Conclusions** Given its unique advantages and greater analytic flexibility, maximum-accuracy machine-learning methods like ODA should be considered as the primary analytic approach in dose–response applications.

## Introduction

Establishing the relationship between various doses of an exposure and a response variable (i.e. outcome) is integral to many studies in health care, whether it is for determining safety (e.g. environmental hazards and drug toxicity), efficacy (e.g. a new drug and multivalued treatments) or adherence/responsiveness (e.g. treatment plan and intervention regimen). Correspondingly, failure to define dose–response relationships may lead to unacceptable toxicity or adverse-effect rates, marginal evidence of effectiveness and a lack of information on how to individualize dosing regimens [1].

Linear statistical models, such as analysis of variance, generalized estimating equations (GEE) or multilevel models are widely used for estimating dose–response relationships. As a family, these parametric models share several drawbacks when used in dose–response studies. First, they assume a linear relationship exists between the dose and the response. Given that orderly, linear relationships rarely exist in health care data, such models may over-estimate or under-estimate the true dose–response relationship

at various points across the range of doses studied. Second, only a limited number of doses are typically tested in most dose–response studies, thus requiring interpolation or extrapolation for any dose not studied. Third, conventional statistical methods are intended for estimating treatment effects at the population level, are generally inaccurate when applied to small samples and are inappropriate when used for making point predictions concerning the response effect for individuals. Several innovative modelling approaches and software have been introduced to account for non-linear relationships between dose and response (e.g. [2,3]). However, these approaches are implemented within a parametric framework, and thus many of the same limitations still apply.

In this paper, we introduce a novel machine-learning approach to establish dose–response relationships. This methodology employs an algorithm called optimal discriminant analysis (ODA) [4,5] to determine if, and to what degree, doses of the exposure can be distinguished based on the distribution of the response variable. By framing the dose–response relationship as a classification problem (i.e. how accurately does the response variable classify

patients into specific dose levels), many of the aforementioned limitations of conventional statistical models are overcome, while obtaining several additional benefits. Specific advantages of ODA as compared with the conventional statistical approach in assessing dose–response relationships include the ability to handle a response variable measured using any metric (from categorical to continuous) and number of doses, insensitivity to skewed data or outliers and the use of accuracy measures that can be widely applied to all classification analyses. ODA also offers the unique ability to ascertain if individuals are likely to be responding to the dose as prescribed based on optimized (maximum accuracy) cut-points on the response variable. Moreover, ODA accepts analytic weights, thereby extending the assessment of a dose–response relationship to observational studies where weights are used for covariate adjustment [6]. Finally, ODA provides the capability to use cross-validation in assessing the generalizability of the model to other individuals outside of the original study sample or to identify solutions that cross-generalize with maximum accuracy when applied across multiple samples.

To illustrate the ODA approach and compare it to a conventional statistical approach (we use a GEE model) for estimating dose–response relationships, we organized the paper as follows. In Section 2, we describe our methods including the data source, an introduction to ODA and the analytic strategy employed in the study. Section 3 reports the results of each approach and a comparison between them. Finally, Section 4 discusses the specific advantages of ODA in assessing dose–response relationships compared with the conventional approach.

## Methods

### Data

We use data from Lang *et al.* [7] that measures the responses of blood flow in the forearm to the intra-arterial administration of isoproterenol (in seven escalating doses: 0, 10, 20, 60, 150, 300 and 400 ng min<sup>-1</sup>) in 9 normotensive black men and 13 normotensive white men. This study found that forearm blood flow responses to isoproterenol were markedly attenuated in normotensive Blacks, whereas the responses were approximately linear in white subjects. It was hypothesized that the mechanisms responsible for blunted vasodilatation in response to the administration of isoproterenol may contribute to enhanced vascular reactivity and influence the pathogenesis of hypertension in Blacks.

These data are ideal for illustrating many of the problems typically encountered in dose–response studies: small sample size, limited number of doses, non-linearity in the dose–response relationship and differential effects by subgroup. The dataset was accessed as a supplement to the book ‘*Statistical Modeling for Biomedical Researchers*’ [8] (found at: <http://biostat.mc.vanderbilt.edu/dupontwd/wddtext/index.html#datasets>).

### A brief introduction to optimal discriminant analysis

Optimal discriminant analysis is a machine-learning algorithm developed more than 25 years ago [9,10] that is capable of analysing data measured on a continuous or interval-level scale, on an ordered scale having relatively few levels or on a qualitative scale

with two or more categories [4,5]. As opposed to parametric statistical models that model a dose–response relationship using a linear function that maximizes variance explained or the value of the likelihood function, the ODA algorithm identifies the cutpoint (or category subset) of the response variable that yields maximum-predictive accuracy in classifying observations into their actual dose. Explicitly maximized classification accuracy may be either the effect strength for sensitivity (ESS) (described in the next section) or overall percent accuracy in classification (PAC) depending on whether or not the investigator chooses to weight the data by prior odds [4,5]. As used herein, for an ordered or continuous response variable and multiple discrete doses (exposure variable), the ODA model has the following form: if response variable score < (threshold value<sub>1</sub>) predict that the observation is from dose A; if response variable score > (threshold value<sub>1</sub>) and ≤ (threshold value<sub>2</sub>) predict that the observation is from dose B; or else, if response variable score > (threshold value<sub>2</sub>) predict that the observation is from dose C, and so forth.

### Assessing statistical significance of optimal discriminant analysis models

Statistical significance (*P* value) for ODA models is computed via Monte Carlo simulation and reported as a permutation probability, such that no distributional assumptions are required of the data and *P* values are exact [5,9]. In study designs involving more than one test of statistical significance (for example, multiple pairwise comparisons between doses), a Sidak Bonferroni-type multiple comparisons methodology is employed to prevent ‘alpha inflation’ and ensure the desired experimentwise *P* value (here, *P* < 0.05) and to inhibit over-fitting [5,11].

### How generalized estimating equations and optimal discriminant analysis deal with repeated observations

The statistical model used to evaluate dose–response relationships must be able to account for autocorrelation when individuals are subjected to multiple doses of the exposure (e.g. increasing doses of a drug). Autocorrelation indicates that any variable measured over time is potentially influenced by previous observations [12]. So in the case of an individual exposed to multiple doses, an individual’s current response at the current dose is likely to be correlated with their previous response to the previous dose. This is in contrast to studies in which individuals are only exposed to a single dose, and thus all observations are independent of each other.

If the response score is autocorrelated in a consistent manner within and between individuals, then estimating a GEE model that accounts for the within-group correlation structure will increase the fit of the model for predicting the response when individuals are tested across multiple doses. This assumes that ‘detecting’ (or failing to detect) autocorrelation is statistically warranted for ubiquitous small samples (e.g. with respect to statistical power and to the veracity of assumptions upon which validity depends), and that autocorrelation-based models retain predictive accuracy when applied in independent validity and generalizability assessments.

In its simplest application, the ODA approach may be used to determine if response scores can be reliably discriminated between two different levels of a stimulus (e.g. dose), without considering

the possible existence of autocorrelation in the response score. In this case, the ODA algorithm identifies the model that maximizes ESS achieved in testing the non-directional (i.e. exploratory, *a posteriori*) alternative hypothesis that response differs between the two doses. If instead it is hypothesized that there is some specific direction of influence of autocorrelation (either positive or negative), then this may be modelled in ODA by testing a directional (i.e. confirmatory, *a priori*) hypothesis: for example, that a greater response will be elicited by a higher dose, or an even more precise *a priori* hypothesis specifying the exact thresholds and decision-making criteria [4,5]. Finally, if instead one is interested in identifying (*vis-à-vis* exploratory research) or in evaluating (*vis-à-vis* confirmatory research) ODA-based *dynamic models*, maximum-predictive-accuracy methods have been developed and found to be more accurate and parsimonious than alternative methods in applications involving single-case as well as multiple-observation time series, and traditionally analysed using methods such as Markov models, turnover tables, test–retest reliability cross-classification methods and so forth. [4,5,11]

### Ecological significance of optimal discriminant analysis models

The issue of how best to interpret the predictive accuracy achieved by a statistical model has been extensively discussed, and wide and broadening consensus asserts that evaluating model performance based solely on statistical significant findings (*P* values) is inappropriate [4,5]. Instead, it is argued that assessment should also include the ability of the model to achieve ‘clinically’ [13,14] or otherwise context-relevant ‘ecologically’ meaningful levels of predictive accuracy [15–18].

Ecological significance of ODA models in particular, and of all classification methodologies in general, is assessed using the ESS statistic. ESS is a normed measure of predictive accuracy that is both chance-corrected (0 = the level of predictive accuracy expected by chance) and maximum-corrected (100 = perfect prediction) [4–6,19]. The cut-points (or category subsets) identified by ODA explicitly maximize the ESS obtained by the ODA model for the total (‘training’) sample. Using ESS, investigators may directly compare the predictive accuracy of different models (corrected for chance) – developed using the same and/or different samples, regardless of structural features such as sample size, skew or ‘outliers’ [5]. Established via simulation research, ESS <25% conventionally indicates a relatively weak effect; values >25% to <50% indicate a moderate effect; values >50% to <75% indicate a relatively strong effect; values >75% to <90% or less indicate a strong effect; and ESS values >90% indicate a very strong effect [4].

### Assessing generalizability of optimal discriminant analysis models

Cross-validation in the dose–response context denotes the generalizability of the model when it is used to classify a sample of individuals other than those utilized for developing the model – for example, new patients prescribed the medication [20]. Commonly-used algorithms for estimating model generalizability include bootstrapping, *k*-fold cross-validation and leave-one-out jackknife (LOO) cross-validation [4,19,21,22]. In this paper, we

use ODA to implement the LOO approach – *n*-fold cross-validation, where *n* is the number of observations in the dataset. Each observation is in turn held out, predicted class membership (i.e. dose) is obtained for each held-out observation and accuracy is determined as success or failure in predicting the actual class membership across held-out observations. The results of all *n* predictions are cumulated to calculate LOO (validity) accuracy, which is then compared with total sample (training model) accuracy. An identical ESS value in both the training and LOO analyses suggests that the ODA model may cross-generalize without a reduction in the predictive accuracy when the model is applied to classify an independent sample. In contrast, an ESS value that is lower in the LOO analysis than in the training analysis suggests that application of the ODA model may yield lower normed predictive accuracy when used to classify independent samples.

### Analytic approach

All analyses were conducted using the data analysed in the original study [7]. For the conventional statistical approach, we estimated a GEE model with forearm blood flow (ml/min/dl) treated as the response (dependent) variable. As in the original analysis, the covariates included isoproterenol dose treated as a categorical ordinal variable with values of 0, 10, 20, 60, 150, 300 and 400 (ng min<sup>-1</sup>); race (Black/White) treated as a binary categorical variable; and an interaction term between dose and race to allow for comparisons of the response between race and dose. The GEE model was estimated using a Gaussian family and identity link with an exchangeable within-group correlation structure to account for autocorrelation within subjects across multiple doses, and robust standard errors [23,24]. All pairwise contrasts (between doses) were adjusted for multiple comparisons using Sidak’s method [25].

For the ODA analyses, three separate models were generated – two separately by race and one pooled. All three models used forearm blood flow (attribute) to predict assignment to each dose level (class variable). Models were directional (i.e. ‘one-sided’), with the *a priori* hypothesis that dose would increase with increasing forearm blood flow. Exact *P* values were estimated using 25 000 Monte Carlo experiments. We controlled the omnibus Type I error rate for the effect of multiple tests of statistical hypotheses by performing a Sidak multiple comparisons procedure to ensure an experimentwise *P* < 0.05 [4], and LOO analysis was conducted to assess the potential cross-generalizability of each ODA model when used to classify individuals other than those in the original study sample.

The presence of paradoxical confounding (also called Simpson’s Paradox) was assessed separately for GEE and ODA analyses. Paradoxical confounding exists when findings of analyses conducted for pooled data (e.g. *P* < 0.05 or *P* > 0.05) are inconsistent with the findings of analyses conducted separately for any of the constituent groups [5,26].


Finally, we evaluated the analytic agreement across corresponding comparisons using ODA, with method (GEE versus ODA) treated as the class variable and finding (experimentwise *P* < 0.05 versus *P* > 0.05) treated as the attribute [5]. That is, we compared corresponding ODA and GEE statistical conclusion findings pooled across all 21 multiple comparisons for the Blacks-only data, for the Whites-only data and for the combined

(Blacks and Whites) data. If GEE and ODA methods agree on statistical conclusions regarding inter-dose–response differences, this indicates cross-analytic-generalizability of the findings. However, if GEE and ODA methods disagree on the statistical conclusions regarding inter-dose–response differences, this may indicate that (1) even though significantly different mean response scores exist between two doses (GEE), dose is not an accurate predictor of individual response (ODA); (2) that  $P$  values generated by GEE (which must satisfy distributional assumptions in order to be valid) are misleading (ODA uses permutation  $P$  values that require no distributional assumptions and are always valid); and/or (3) there is inadequate statistical power (e.g. due to small sample, class sample size imbalance and/or sparse data) to warrant analytic comparison [5].

Stata 14.1 (StataCorp., College Station, TX, USA) was used to conduct all GEE analyses and the Sidak adjustments for multiple testing after generating the GEE and ODA models [27]. ODA analyses were performed using ODA Software [4].

## Results

Figure 1 illustrates the means and 95% confidence intervals of the response variable (forearm blood flow) for each dose, separately for white and black subjects. Table 1 presents the numeric results of the GEE-based analysis. As reported by Lang *et al.* [7], forearm blood flow increases with escalating dose in the white subjects, while the dose–response relationship appears blunted in the black subjects. Examination of confidence interval overlap indicates that the difference between the black and white cohorts in forearm blood flow becomes statistically significant commencing at a dose of  $20 \text{ ng min}^{-1}$ . Interestingly, the pooled data show a similarly strong dose–response relationship to that of the white cohort (Sidak adjusted  $P$  values for the GEE pairwise comparisons between doses are presented in Appendix Tables A1–A3). In the white cohort, all pairwise dose–response comparisons are statistically significant at the experimentwise  $P < 0.05$  level except for the 0 to  $10 \text{ ng min}^{-1}$  comparison (Appendix Table A2).



**Figure 1** Forearm blood flow responses to Isoproterenol in normotensive Blacks ( $n=9$ ) and Whites ( $n=12$ ), from [7]. Values shown are means and 95% confidence intervals.

Conversely, in the black cohort, only 13 of the 21 pairwise comparisons are statistically significant at the experimentwise criterion (Appendix Table A3). When the data are pooled, all pairwise comparisons are statistically significant except for the 300 to  $400 \text{ ng min}^{-1}$  comparison (Appendix Table A1). This clearly indicates the presence of paradoxical confounding [26]. In total, there were eight instances of confounding in the GEE analyses: a significant effect for the pooled sample for the 0–10 dose comparison, but no effect for either cohort; a significant effect for the pooled and white samples, but not for the black sample, for the 10–20, 10–400, 20–400, 60–150, 60–400 and 150–400 comparisons; and a significant effect for the white sample, but not for the pooled or black samples, for the 300–400 comparison.

Table 2 presents the results of the ODA-based analysis, including the cut-points (decision thresholds) on the forearm blood flow variable that are associated with each dose of isoproterenol (these cut-points explicitly maximize training model ESS), and the corresponding model *sensitivity* (true positive rate) – the proportion of individuals that are correctly predicted by the ODA model to be on each specific dose [28]. To facilitate interpretation of these values, we use the  $20 \text{ ng min}^{-1}$  dose of the pooled data as an example. The ODA model predicts that an individual was on a dose of  $20 \text{ ng min}^{-1}$  if their forearm blood flow was  $>2.945$  ( $\text{ml min dl}^{-1}$ ) and  $\leq 6.855$  ( $\text{ml min dl}^{-1}$ ). The ODA model correctly classified 71.43% of individuals at this dose in the training analysis (Table 2). In the LOO analysis, the sensitivity at this dose remained unchanged, suggesting that the model can predict with relatively strong accuracy, which among newly tested subjects is on the  $20 \text{ ng min}^{-1}$  dose.

In the white cohort (Table 2), the sensitivity for the overall sample ranges between 33.33% at doses of 150 and 300 and 66.67% at a dose of  $20 \text{ ng min}^{-1}$ . This corresponds to an ESS value of 40.28%, indicating a moderate effect [4]. LOO analysis resulted in a decline in ESS to 27.78%, suggesting moderate generalizability to subjects outside of the training cohort.

In the black cohort (Table 2), the sensitivity for the overall sample ranges from 11.11% at the 400 level dose to 100% at the 300 level dose. This corresponds to an ESS value of 40.74%, indicating a moderate effect. Similar to the white cohort, LOO analysis in the black cohort also resulted in a decline in ESS (to 29.63%) suggesting moderate generalizability.

When the data are pooled (Table 2), a different pattern in the dose–response relationship emerges. Here, sensitivity ranges from a low of 4.76% at a dose of  $60 \text{ ng min}^{-1}$  to a high of 71.43% at a dose of  $20 \text{ ng min}^{-1}$ . This corresponds to a moderate ESS of 31.75%, which is substantially lower than the ESS that was obtained when either cohort was evaluated separately (paradoxical confounding, by definition). As in the analysis for the separate cohorts of white and black observations, LOO analysis ESS declined (26.98%) suggesting moderate generalizability.

All Sidak adjusted  $P$  values for the ODA pairwise comparisons between doses are presented in Appendix Tables A4–A6. In the white cohort, 13 of the 21 pairwise comparisons are statistically significant (Appendix Table A5), whereas in the black cohort, only 8 of the 21 pairwise comparisons are statistically significant (Appendix Table A6). When the data are pooled, 12 of the 21 pairwise comparisons are statistically significant (Appendix Table A4). In total, there were four instances of paradoxical

**Table 1** Forearm blood flow responses to isoproterenol in normotensive Blacks ( $n = 9$ ) and Whites ( $n = 12$ ), from [7]

	Dose of isoproterenol ( $\text{ng min}^{-1}$ )							<i>P</i> value
	0	10	20	60	150	300	400	
All								
Mean	2.468	3.057	5.067	10.610	12.529	15.424	16.948	<0.0001
SE	0.253	0.386	0.588	1.638	1.911	1.923	2.404	
95% CI	1.971, 2.964	2.300, 3.814	3.914, 6.219	7.399, 13.821	8.784, 16.274	11.656, 19.193	12.237, 21.659	
Whites								
Mean	2.683	3.417	6.458	14.592	17.250	20.200	23.833	<0.0001
SE	0.411	0.632	0.775	2.170	2.518	2.390	2.501	
95% CI	1.877, 3.488	2.178, 4.655	4.940, 7.976	10.338, 18.845	12.315, 22.185	15.515, 24.885	18.932, 28.734	
Blacks								
Mean	2.181	2.578	3.211	5.302	6.234	9.057	7.768	0.001
SE	0.179	0.238	0.335	0.698	0.720	1.301	1.769	
95% LCI	1.829, 2.533	2.112, 3.043	2.555, 3.867	3.934, 6.670	4.822, 7.647	6.506, 11.607	4.300, 11.236	
Diff (Blacks versus Whites)								
SE	0.448	0.675	0.844	2.280	2.619	2.722	3.063	
95% CI	-1.380, 0.378	-2.162, 0.484	-4.901, -1.593	-13.758, -4.821	-16.148, -5.883	-16.477, -5.809	-22.069, -10.062	
<i>P</i> value	0.264	0.214	0.0001	<0.0001	<0.0001	<0.0001	<0.0001	

Results are from a generalized estimating equation model in which forearm blood flow was regressed on dose, race and an interaction term of the two.

**Table 2** Forearm blood flow responses to isoproterenol in normotensive Blacks ( $n = 9$ ) and Whites ( $n = 12$ ), from [7]

	Dose of isoproterenol ( $\text{ng min}^{-1}$ )							ESS (%)	<i>P</i> value
	0	10	20	60	150	300	400		
All									
Cut-points	$\leq 2.53$	$>2.53$ & $\leq 2.945$	$>2.945$ & $\leq 6.855$	$>6.855$ & $\leq 7.355$	$>7.355$ & $\leq 9.85$	$>9.85$ & $\leq 21.0$	$>21.0$		
Sens-train (%)	66.67	28.57	71.43	4.76	23.81	57.14	38.10	31.75	<0.001
Sens-LOO (%)	66.67	28.57	71.43	0.00	14.29	47.62	33.33	26.98	
Whites									
Cut-points	$\leq 2.15$	$>2.15$ & $\leq 3.95$	$>3.95$ & $\leq 7.3$	$>7.3$ & $\leq 12.05$	$>12.05$ & $\leq 17.45$	$>17.45$ & $\leq 21.2$	$>21.2$		
Sens-train (%)	50.00	58.33	66.67	41.67	33.33	33.33	58.33	40.28	<0.001
Sens-LOO (%)	50.00	41.67	58.33	25.00	25.00	25.00	41.67	27.78	
Blacks									
Cut-points	$\leq 2.53$	$>2.53$ & $\leq 2.945$	$>2.945$ & $\leq 3.68$	$>3.68$ & $\leq 4.085$	$>4.085$ & $\leq 4.375$	$>4.375$ & $\leq 18.95$	$>18.95$		
Sens-train (%)	77.78	44.44	44.44	33.33	33.33	100.00	11.11	40.74	<0.001
Sens-LOO (%)	66.67	33.33	44.44	33.33	0.00	88.89	11.11	29.63	

Results are from an optimal discriminant analysis. Values represent cut-points on the response variable (forearm blood flow).

Sens, sensitivity; LOO, leave-one-out cross-validation; ESS, effect strength for sensitivity.

confounding in the ODA analyses. There was a significant effect for the pooled sample for the 20–150 dose comparison, but no effect for either cohort; a significant effect for the white sample, but not for the pooled or black samples, for the 10–20 comparison; and a significant effect for the white and the pooled samples, but not for the black sample, for the 0–20 and 20–400 comparisons.

The final analyses evaluate inter-method agreement across the multiple inferential paired-comparisons tests performed (Table 3). Isomorphic results were obtained for statistical conclusion findings obtained in analysis of data for the pooled sample and in analysis of data for Whites-only. For these samples, only one of the eight paradoxical findings for the GEE model (the 20–400 paired-comparison) has the same corresponding paradoxical

**Table 3** Statistical conclusion agreement between GEE and ODA analyses performed for 21 paired-comparisons

	ODA, $P < 0.05$	ODA, $P > 0.05$	ESS	<i>P</i> value
Whites, Pooled				
GEE, $P < 0.05$	12	8		
GEE, $P > 0.05$	0	1		
Blacks				
GEE, $P < 0.05$	7	6	41.4	0.09
GEE, $P > 0.05$	1	7		

GEE, generalized estimating equation; ODA, optimal discriminant analysis; ESS, effect strength for sensitivity.

finding for the ODA model. Comparing GEE (Appendix Tables A1 and A4) and ODA (Appendix Tables A2 and A5), statistical conclusions across the 21 paired-comparisons yields  $ESS = 60.0$ ,  $P < 0.43$  (Table 3). Thus, there is no evidence of statistically significant agreement (i.e. inter-method reliability [5]) of the statistical conclusions reached by GEE and ODA when aggregated over 21 paired-comparisons for pooled or Whites-only data. However, comparing the 21 GEE and ODA paired-comparisons for Blacks-only (Appendix Tables A3 and A6) yields  $ESS = 41.4$ ,  $P < 0.09$  (Table 3). Thus, there is evidence of marginally reliable agreement of statistical conclusions reached by GEE and ODA methods, aggregated over 21 paired-comparisons, for Blacks-only data.

These inter-method agreement analyses had low statistical power because of the small number of times that both methods agreed that a multiple comparison was not statistically significant (Table 3) [5]. A consistent point of disagreement involved multiple comparisons for which GEE reported  $P < 0.05$  (accept the alternative hypothesis) and ODA reported  $P > 0.05$  (reject the alternative hypothesis). This suggests that, in the present data, ODA (providing exact  $P$  values with unquestioned validity [4,5]) produced more conservative estimates of statistical significance than GEE – for which the validity of  $P$  depends upon underlying distributional assumptions being satisfied [8].

## Discussion

Classification is the most popular data mining application in healthcare research, and it has been used to improve diagnostic accuracy, identify high-risk patients and to extract concepts in unstructured data, for example [29]. The present paper focuses on the use of classification for identifying dose–response relationships. Using a published dataset possessing characteristics exemplifying many dose–response studies (small sample size, limited number of doses, non-linearity in the dose–response relationship and differential effects by subgroup), the present article demonstrates that ODA can perform the usual functions of conventional linear models (i.e. testing for statistical significance of the overall model and *post hoc* pairwise comparisons between doses) while offering several key advantages over those models.

First, the ODA algorithm, with its associated measure of classification performance (ESS) and non-parametric permutation tests, can be universally applied to any response variable type and number of doses, and is not affected by skewed (non-linear) data, or outliers – a concern that may arise in the context of meeting assumptions underlying the validity of the estimated  $P$  value obtained using the conventional approach. In the current example, ODA was consistently more conservative than GEE when comparing between models across the multiple inferential tests performed.

Second, ODA models explicitly, by mathematical formulation, maximize the accuracy of point predictions made at the individual level (this may be compared with the context of the population level that is assumed by conventional parametric statistical methods) for the model that maximizes (weighted) ESS [4]. This feature of ODA has tremendous value for determining whether patients are adherent, or responding, to their prescribed drug regimens (e.g. [30,31]). Physicians monitoring the level of a patient's

response variable (i.e. blood or urine levels of a metabolite, etc.) can cross reference those values to the cutpoint range generated by ODA to determine the likelihood that the patient is responding to the prescribed dose. The sensitivity of the ODA model observed for each dose provides the physician with the level of predictive accuracy to expect at any particular dose. High model sensitivity would provide the physician with more confidence that the patient is actually on the prescribed dose than if the model sensitivity was low. Likewise, the sensitivity estimates derived from the LOO analysis allows the physician to further consider the likelihood of adherence to that dose for new patients, existing patients newly prescribed the drug or patients with somewhat different characteristics than those from the original study population. In the current data, sensitivities for the various doses were of moderate strength (for training and LOO analyses), suggesting that the models provide moderately accurate predictions of dose ‘assignment’ based on the distribution of the response variable.

Third, ODA accepts analytic weights, thereby extending this individual-level assessment of a dose–response relationship to observational studies where weights are used for covariate adjustment [32–37]. This feature is particularly valuable, for example, in after-market drug studies, exposure to environmental hazards or multivalued interventions in which self-selection is likely to bias the outcome.

Optimal discriminant analysis clearly offers important advantages and presents greater analytic flexibility than conventional parametric approaches for estimating dose–response relationships. Nevertheless, ODA and conventional approaches are subject to two limiting factors relating to data. First, there is the common limitation of a small sample. Small and highly imbalanced sample sizes offer little statistical power for testing *a priori* hypotheses and can limit the predictive accuracy of the model – particularly when applied in cross-generalizability analysis. Second, the constitution of the training sample, and of any independent validation samples, warrants consideration. Combining data from observations representing two or more strata (e.g. any possible combination of white and black, young and old, sick and healthy and men and women) may produce erroneous results for one or more of the constituent groups. Such paradoxical confounding occurs in studies involving multiple subjects and in studies involving single-case longitudinal (time-series) designs. Sometimes two or more groups simply cannot be combined without inducing confounding, because of structural differences among the groups [5].

In summary, this paper introduced a novel approach for modeling dose–response relationships that uses a machine-learning algorithm to determine the degree to which doses of the exposure can be distinguished based on the distribution of the response variable. The methodology offers important advantages and presents greater analytic flexibility than conventional parametric approaches, and thus should be considered as an alternative – if not the preferred approach – in dose–response applications.

## Acknowledgements

We wish to thank Julia Adler-Milstein for her review and feedback on the manuscript. Dr Yarnold's work was partly funded by a grant from the National Cancer Institute (1R01CA165609-01A1).

## References

1. Peck, C. C., Barr, W. H., Benet, L. Z., *et al.* (1992) Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. *Journal of Pharmaceutical Sciences*, 81, 605–610.
2. Royston, P. (2014) A smooth covariate rank transformation for use in regression models with a sigmoid dose–response function. *Stata Journal*, 14, 329–341.
3. Di Veroli, G. Y., Fomari, C., Goldlust, I., Mills, G., Koh, S. B., Bramhall, J. L., Richards, F. M. & Jodrell, D. I. (2015) An automated fitting procedure and software for dose–response curves with multiphasic features. *Scientific reports*, 5, 1–11.
4. Yarnold, P. R. & Soltysik, R. C. (2005) *Optimal Data Analysis: A Guidebook with Software for Windows*. Washington, DC: APA Books.
5. Yarnold, P. R. & Soltysik, R. C. (2016) *Maximizing Predictive Accuracy*. Chicago, IL: ODA Books. doi: 10.13140/RG.2.1.1368.3286
6. Linden, A. & Yarnold, P. R. (2016) Using machine learning to assess covariate balance in matching studies. *Journal of Evaluation in Clinical Practice*, 22, 844–850.
7. Lang, C. C., Stein, C. M., Brown, R. M., Deegan, R., Nelson, R., He, H. B., Wood, M. & Wood, A. J. (1995) Attenuation of isoproterenol-mediated vasodilatation in blacks. *New England Journal of Medicine*, 333, 155–160.
8. Dupont, W. D. (2009) *Statistical Modeling for Biomedical Researchers*. Cambridge, U.K: Cambridge University Press.
9. Yarnold, P. R. & Soltysik, R. C. (1991) Theoretical distributions of optima for univariate discrimination of random data. *Decision Sciences*, 22, 739–752.
10. Carmony, L., Yarnold, P. R. & Naeymi-Rad, F. (1997) One-tailed Type I error rates for balanced two-category UniODA with a random ordered attribute. *Annals of Operations Research*, 74, 223–238.
11. Linden, A. & Yarnold, P.R. (2016) Using machine learning to identify structural breaks in single-group interrupted time series designs. *Journal of Evaluation in Clinical Practice*, 22, 851–855.
12. Linden, A., Adams, J. & Roberts, N. (2003) Evaluating disease management program effectiveness: an introduction to time series analysis. *Disease Management*, 6, 243–255.
13. Feinstein, A. R. (1988) Statistical significance versus clinical importance. *Quality of Life and Cardiovascular Care*, 4, 99–102.
14. Kraemer, H. C. (1992) *Evaluating Medical Tests*. Newbury Park, CA: Sage.
15. Baus, J. W. & Gose, E. E. (1995) Leukocyte pattern recognition. *IEEE Transactions on Systems, Man, and Cybernetics*, SMC-2, 513–526.
16. Eisenbeis, R. A. (1977) Pitfalls in the application of discriminant analysis in business, finance, and economics. *The Journal of Finance*, 32, 875–900.
17. Nishikawa, K., Kubota, Y. & Ooi, T. (1983) Classification of proteins into groups based on amino acid composition and other characters, II: grouping into four types. *Journal of Biochemistry*, 94, 997–1007.
18. Yarnold, P. R. (1992) Statistical analysis for single-case designs. In *Social Psychological Applications to Social Issues: Vol. 2. Methodological Issues in Applied Social Research* (eds F. B. Bryant, L. Heath, E. Posavac, J. Edwards, S. Tindale, E. Henderson & Y. Suarez-Balcazar), pp. 177–197. New York: Plenum.
19. Linden, A., & Yarnold, P.R. (2016) Using data mining techniques to characterize participation in observational studies. *Journal of Evaluation in Clinical Practice*, 22, 835–843.
20. Linden, A., Adams, J. & Roberts, N. (2004) The generalizability of disease management program results: getting from here to there. *Managed Care Interface*, 17, 38–45.
21. Witten, I. H., Frank, E. & Hall, M. A. (2011) *Data Mining: Practical Machine Learning Tools and Techniques*, 3rd edn. San Francisco: Morgan Kaufmann.
22. Linden, A., Adams, J. & Roberts, N. (2005) Evaluating disease management program effectiveness: an introduction to the bootstrap technique. *Disease Management and Health Outcomes*, 13, 159–167.
23. Huber, P. J. (1967) The behavior of maximum likelihood estimates under nonstandard conditions. In Vol. 1 of *Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability*, pp. 221–233. Berkeley: University of California Press.
24. White, H. L. Jr. (1980) A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. *Econometrica*, 48, 817–838.
25. Sidak, Z. (1967) Rectangular confidence regions for the means of multivariate normal distributions. *Journal of the American Statistical Association*, 62, 626–633.
26. Yarnold, P. R. (1996) Characterizing and circumventing Simpson's paradox for ordered bivariate data. *Educational and Psychological Measurement*, 56, 430–442.
27. Newson, R. B. (2010) Frequentist q-values for multiple-test procedures. *The Stata Journal*, 10, 568–584.
28. Linden, A. (2006) Measuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristic (ROC) analysis. *Journal of Evaluation in Clinical Practice*, 12, 132–139.
29. Iavindrasana, J., Cohen, G., Depeursinge, A., Müller, H., Meyer, R. & Geissbuhler, A. (2009) Clinical data mining: a review. In *IMIA Yearbook of Medical Informatics*. (eds A. Geissbuhler, C. Kulikowski), 48, Suppl 1, pp. 121–133.
30. Couto, J., Webster, L., Romney, M., Leider, H. & Linden, A. (2009) Using an algorithm applied to urine drug screening to assess adherence to an OxyContin regimen. *Journal of Opioid Management*, 5, 359–364.
31. Couto, J., Webster, L., Romney, M., Leider, H. & Linden, A. (2011) Use of an algorithm applied to urine drug screening to assess adherence to a hydrocodone regimen. *Journal of Clinical Pharmacology & Therapeutics*, 36, 200–207.
32. Linden, A. & Adams, J. L. (2010a) Using propensity score-based weighting in the evaluation of health management programme effectiveness. *Journal of Evaluation in Clinical Practice*, 16, 175–179.
33. Linden, A. & Adams, J. L. (2010b) Evaluating health management programmes over time. Application of propensity score-based weighting to longitudinal data. *Journal of Evaluation in Clinical Practice*, 16, 180–185.
34. Linden, A. & Adams, J. L. (2011) Applying a propensity-score based weighting model to interrupted time series data: improving causal inference in program evaluation. *Journal of Evaluation in Clinical Practice*, 17, 1231–1238.
35. Linden, A. & Adams, J. L. (2012) Combining the regression-discontinuity design and propensity-score based weighting to improve causal inference in program evaluation. *Journal of Evaluation in Clinical Practice*, 18, 317–325.
36. Linden, A. (2014) Combining propensity score-based stratification and weighting to improve causal inference in the evaluation of health care interventions. *Journal of Evaluation in Clinical Practice*, 20, 1065–1071.
37. Linden, A., Uysal, S. D., Ryan, A. & Adams, J. L. (2016) Estimating causal effects for multivalued treatments: a comparison of approaches. *Statistics in Medicine*, 35, 534–552.

## Appendix

**Table A1** Sidak adjusted *P* values for all pairwise comparisons following generalized estimating equations for pooled data

	Dose of isoproterenol (ng min <sup>-1</sup> )					
	0	10	20	60	150	300
0						
10	0.047					
20	<0.001	<0.001				
60	<0.001	<0.001	<0.001			
150	<0.001	<0.001	<0.001	<0.001		
300	<0.001	<0.001	<0.001	<0.001	<0.001	
400	<0.001	<0.001	<0.001	<0.001	<0.001	0.375

**Table A2** Sidak adjusted *P* values for all pairwise comparisons following generalized estimating equations for Whites only

	Dose of isoproterenol (ng min <sup>-1</sup> )					
	0	10	20	60	150	300
0						
10	0.278					
20	<0.001	<0.001				
60	<0.001	<0.001	<0.001			
150	<0.001	<0.001	<0.001	0.007		
300	<0.001	<0.001	<0.001	<0.001	0.004	
400	<0.001	<0.001	<0.001	<0.001	<0.001	0.006

**Table A3** Sidak adjusted *P* values for all pairwise comparisons following generalized estimating equations for Blacks only

	Dose of isoproterenol (ng min <sup>-1</sup> )					
	0	10	20	60	150	300
0						
10	0.640					
20	0.014	0.336				
60	<0.001	0.001	0.027			
150	<0.001	<0.001	<0.001	0.161		
300	<0.001	<0.001	<0.001	0.01	0.022	
400	0.028	0.092	0.178	0.966	0.999	0.896

**Table A4** Sidak adjusted *P* values for all pairwise comparisons following optimal discriminant analysis for pooled data

	Dose of isoproterenol (ng min <sup>-1</sup> )					
	0	10	20	60	150	300
0						
10	0.969					
20	<0.001	0.057				
60	<0.001	<0.001	0.167			
150	<0.001	<0.001	0.006	1.000		
300	<0.001	<0.001	<0.001	0.641	0.883	
400	<0.001	<0.001	<0.001	0.886	0.980	1.000

**Table A5** Sidak adjusted *P* values for all pairwise comparisons following optimal discriminant analysis for Whites only

	Dose of isoproterenol (ng min <sup>-1</sup> )					
	0	10	20	60	150	300
0						
10	1.000					
20	0.017	0.018				
60	<0.001	<0.001	0.076			
150	<0.001	<0.001	0.072	1.000		
300	<0.001	<0.001	<0.001	0.942	1.000	
400	<0.001	<0.001	<0.001	0.662	0.943	1.000

**Table A6** Sidak adjusted *P* values for all pairwise comparisons following optimal discriminant analysis for Blacks only

	Dose of isoproterenol (ng min <sup>-1</sup> )					
	0	10	20	60	150	300
0						
10	0.964					
20	0.290	0.965				
60	0.006	0.052	0.308			
150	<0.001	0.012	0.067	1.000		
300	<0.001	<0.001	0.009	0.740	0.983	
400	0.006	<0.001	0.067	1.000	1.000	1.000